Recombinant Mouse IL-17RA/IL-17R Fc Chimera Protein, CF

• Reactivity: Mu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Mouse IL-17RA/IL-17R Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its ability to inhibit IL-17-induced IL-6 secretion by NIH‑3T3 mouse embryonic fibroblast cells. The ED₅₀ for this effect is 0.015-0.075 µg/mL in the presence of 10 ng/mL of recombinant mouse IL-17.
• Source: Mouse myeloma cell line, NS0-derived mouse IL-17 RA/IL-17 R protein
  

  Mouse IL-17 RA/IL-17 R (Ser32-Trp322) Accession # Q60943	IEGRMDP	Mouse IgG2A (Glu98-Lys330)
  N-terminus		C-terminus

• Accession #: Q60943
• N-terminal Sequence: Ser32
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Gene: Il17ra
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain
• Endotoxin Note: <0.01 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 60.4 kDa (monomer).
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 80-95 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain
• Reconstitution Instructions: Reconstitute at 100 μg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Mouse IL-17RA/IL-17R Fc Chimera Protein, CF

• CD217 antigen
• CD217
• Cdw217
• CDw217interleukin 17 receptor
• hIL-17R
• IL-17 R
• IL-17 RA
• IL-17 receptor A
• IL17RA
• IL-17RA
• IL-17RAMGC10262
• IL17Rinterleukin-17 receptor A
• interleukin 17 receptor A

Background

IL-17 R, also known as IL-17 RA, is a 120 kDa type I transmembrane glycoprotein protein that plays a central role in inflammatory responses (1-3). Mature mouse IL‑17 R consists of a 291 amino acid (aa) extracellular domain, a 21 aa transmembrane segment, and a 521 aa cytoplasmic domain (4). The cytoplasmic domain contains a region homologous to the TIR domain of the TLR/IL-1 R family (5). Mouse IL-17 R shares 84% and 72% aa sequence identity with rat and human IL-17 R, respectively. Within the extracellular domain, it shares 18%-25% sequence identity with mouse IL-17 RB, C, D, and E. While the expression of IL-17 is restricted to activated T cells, IL-17 R exhibits a broad tissue distribution (4). Even in the absence of ligand, IL-17 R exists on the cell surface as a multimer (6). IL-17 R can bind IL-17 but must associate with IL-17 RC to transduce signals (7, 8). Interestingly, human IL-17 R does not appear to form productive complexes with mouse IL-17 RC (8). The IL-17 R can also signal in response to IL-17F (9). IL-17 R ligation promotes T cell activation and the production of IL-6, G-CSF, SCF, and multiple pro‑inflammatory chemokines (4, 7, 9, 10). IL-17A and IL-17F synergize with TNF-alpha in the induction of CXCL1, G-CSF, and IL-6 (9, 11). This effect requires the presence of both TNF RI and TNF RII (9). IL-17 interactions with IL-17 R also inhibit the TNF-alpha induced up-regulation of fibroblast CCL5 and VCAM-1 (11). CCL5 and VCAM-1 induced effects are differentially sensitive to blockade with IL-17 R specific antibodies, suggesting that IL-17 R triggers divergent intracellular signals (11). In vivo, IL‑17 R activity is important for increased generation of neutrophils and their recruitment to sites of inflammation (10, 12, 13). IL-17 R is required for host defense against microbial infection and for the progression of arthritis from inflammation to destructive joint erosion (10, 13).

1. Iwakura, Y. and H. Ishigame (2006) J. Clin. Invest. 116:1218.
2. Moseley, T.A. et al. (2003) Cytokine Growth Factor Rev. 14:155.
3. Kawaguchi, M. et al. (2004) J. Allergy Clin. Immunol. 114:1265.
4. Yao, Z. et al. (1995) Immunity 3:811.
5. Novatchkova, M. et al. (2003) Trends Biochem. Sci. 28:226.
6. Kramer, J.M. et al. (2006) J. Immunol. 176:711.
7. Hymowitz, S.G. et al. (2001) EMBO J. 20:5332.
8. Toy, D. et al. (2006) J. Immunol. 177:36.
9. McAllister, F. et al. (2005) J. Immunol. 175:404.
10. Ye, P. et al. (2001) J. Exp. Med. 194:519.
11. Schnyder, B. et al. (2005) Cytokine 31:191.
12. Tan, W. et al. (2006) J. Immunol. 176:6186.
13. Lubberts, E. et al. (2005) J. Immunol. 175:3360.

Publications for IL-17RA/IL-17R (4481-MR)(1)

Publication using 4481-MR

• Rickel EA, Siegel LA, Yoon BR, Rottman JB, Kugler DG, Swart DA, Anders PM, Tocker JE, Comeau MR, Budelsky AL Identification of functional roles for both IL-17RB and IL-17RA in mediating IL-25-induced activities. J. Immunol., 2008-09-15;181(6):4299-310. 2008-09-15 [PMID: 18768888] (Immunization, Rat)

Bioinformatics

• Gene Symbol: Il17ra
• Uniprot:
  • Q60943()